ReviewFrontiers in immunology2025
The gut microbiota and its metabolites: novel therapeutic targets for inflammatory bowel disease.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Trial
- Metabolite-Related Evidence Linking Metabolic Measures to Patient-Reported Outcomes in Inflammatory Bowel Disease: A Critical Narrative Review.Metabolites · 2026Review
- Associations of Inosine with Gut Microbiota, Metabolic Indicators, and Fluid Homeostasis in Kidney-Related Diarrhea.International journal of molecular sciences · 2026Article
- Review
- Plant-Derived Foods and Medicines as Modulators of the Gut Microbiome: Molecular Interactions and Implications for Disease and Therapy.Molecules (Basel, Switzerland) · 2026Review
- Interplay of Microbiome, Oxidative Stress and Inflammation in Health and Disease.Antioxidants (Basel, Switzerland) · 2026Review
- Targeted expression of the immunomodulatory peptide Scy by engineeredFrontiers in immunology · 2026Article
- Engineering probiotic consortia to improve chemotherapy tolerance and reduce toxicity in breast cancer patients: a new frontier in supportive precision oncology.Oncology reviews · 2026Review
- Therapeutic potential of ginseng and its bioactive compounds in inflammatory bowel disease: current evidence and future directions.Frontiers in immunology · 2026Review
- Decoding the microbial blueprint of pancreatic cancer.Frontiers in medicine · 2026Review
- Probiotic drug interactions in ulcerative colitis: a microbiota and metabolite perspective.Frontiers in microbiology · 2026Review
- Baseline gut microbiome features associated with fecal calprotectin response to exclusive enteral nutrition in pediatric Crohn's disease.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) pathogenesis is critically influenced by gut microbiota dysbiosis and perturbations in associated metabolites. This review outlines current IBD diagnostic and therapeutic paradigms, highlighting the persistent focus on the management of inflammatory symptoms and the absence of curative interventions. We elucidate the mechanistic links between gut microbiota dysregulation and IBD progression, with an emphasis on the immunomodulatory functions of microbial metabolites-specifically short-chain fatty acids (SCFAs), bile acids (BAs), and tryptophan (Trp) metabolism-in maintaining intestinal barrier integrity and attenuating inflammation. Furthermore, we evaluate microbiota-targeted therapeutic strategies, including probiotics, fecal microbiota transplantation (FMT), and metabolite-based interventions, as novel approaches for IBD management. This synthesis aims to inform future therapeutic development and accelerate the clinical translation of microbiota-modulating regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.